PT Jayamas Medica Industri Tbk (ISX:OMED) EBIT: Rp506,733 Mil (TTM As of Mar. 2026)


ISX:OMED PT Jayamas Medica Industri Tbk ISX:OMED
90 GF Score
Price Rp208.00
GF Value Rp236.50
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is PT Jayamas Medica Industri Tbk EBIT?

PT Jayamas Medica Industri Tbk ISX:OMED +0.97% 90 EBIT is Rp506,733 Mil as of Mar. 2026. GuruFocus rates ISX:OMED with a GF Score™ of 90/100 and a GF Value™ of Rp236.50 (Modestly Undervalued). The stock has 2 warning signs investors should review.

PT Jayamas Medica Industri Tbk's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was Rp132,243 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was Rp506,733 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PT Jayamas Medica Industri Tbk's annualized ROC % for the quarter that ended in Mar. 2026 was 20.04%. PT Jayamas Medica Industri Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 36.80%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PT Jayamas Medica Industri Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.20%.


PT Jayamas Medica Industri Tbk  (ISX:OMED) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PT Jayamas Medica Industri Tbk's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=445583.58 * ( 1 - 22.2% )/( (1667741.873 + 1791241.741)/ 2 )
=346664.02524/1729491.807
=20.04 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3197846.92 - 186779.176 - ( 1343325.871 - max(0, 235319.635 - 2437034.105+1343325.871))
=1667741.873

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3321884.497 - 163315.431 - ( 1367327.325 - max(0, 225425.533 - 2497787.467+1367327.325))
=1791241.741

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PT Jayamas Medica Industri Tbk's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=528973.664/( ( (513361.667 + max(883793.069, 0)) + (527991.539 + max(949479.617, 0)) )/ 2 )
=528973.664/( ( 1397154.736 + 1477471.156 )/ 2 )
=528973.664/1437312.946
=36.80 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(279005.922 + 746435.22 + 61814.766) - (186779.176 + 0 + 16683.663)
=883793.069

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(297947.319 + 758276.976 + 68693.362) - (163315.431 + 0 + 12122.609)
=949479.617

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PT Jayamas Medica Industri Tbk's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=506732.531/4523387.416
=11.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Jayamas Medica Industri Tbk EBIT Related Terms


PT Jayamas Medica Industri Tbk EBIT Historical Data

* Premium members only.

The historical data trend for PT Jayamas Medica Industri Tbk's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Jayamas Medica Industri Tbk EBIT Chart

PT Jayamas Medica Industri Tbk Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 750,908.39 392,762.02 344,856.77 413,607.63 472,112.36

PT Jayamas Medica Industri Tbk Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97,623.25 102,783.71 128,789.63 142,915.78 132,243.42

ISX:OMED vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Jayamas Medica Industri Tbk EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PT Jayamas Medica Industri Tbk's EV-to-EBIT falls into.


ISX:OMED
90GF Score
PT Jayamas Medica Industri Tbk ISX:OMED
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Jayamas Medica Industri Tbk EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp506,733 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of Rp506,733 Mil mean?
PT Jayamas Medica Industri Tbk (ISX:OMED) has a EBIT of Rp506,733 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Jayamas Medica Industri Tbk.
Is PT Jayamas Medica Industri Tbk's EBIT too high?
PT Jayamas Medica Industri Tbk's current EBIT is Rp506,733 Mil. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's EBIT compare to ISRG and BDX?
PT Jayamas Medica Industri Tbk's EBIT of Rp506,733 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Jayamas Medica Industri Tbk. PT Jayamas Medica Industri Tbk's current EBIT is Rp506,733 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp236.50, compared to a current price of Rp208.00 — trading 12.1% below its estimated fair value. The current EBIT is Rp506,733 Mil. PT Jayamas Medica Industri Tbk's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current EBIT is Rp506,733 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?

Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued. The current stock price of Rp208.00 is trading 12.1% below its estimated GF Value™ of Rp236.50. GuruFocus considers PT Jayamas Medica Industri Tbk to be Modestly Undervalued.

Key valuation signals for ISX:OMED:

  • EBIT: Rp506,733 Mil
  • GF Value™: Rp236.50 vs. price of Rp208.00 (12.1% below fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Jayamas Medica Industri Tbk Business Description

Address Sebelah Selatan Jalan By Pass RT 05 / RW 01, Sidomojo Village, Krian District, Sidoarjo, Jawa Timur, East Java, IDN, 61262
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
90GF Score

Get the complete analysis for ISX:OMED

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp208.00
Price
Rp236.50
GF Value